Free-text search
Content Types
-
Sanofi Sweden: ”We will work for more clinical trials”
Sanofi Sweden may represent only a modest share of the global Sanofi group, which employs nearly 80,000 people, but it still makes a significant research impact...
-
EVENT | As fewer and fewer new medicines reach Swedish patients – can Swedish life science...
Breakfast Event | September 30 | 8.00-10.00 | SWEDEN
-
Upgraded outlook sends Bavarian Nordic shares higher
The Danish vaccine company Bavarian Nordic’s share price rose notably on Friday following a quarterly report showing higher‑than‑expected revenue and an upgraded outlook.
-
The vaccine has saved 94 million lives – but measles is spreading again
A disease we once believed belonged to the past is now resurging in both Europe and the United States. In Sweden, 24 cases of the disease have so far been repor...
-
Implantica secures FDA approval: “Culmination of many years of development”
Swedish-founded Implantica has received Premarket Approval (PMA) from the FDA for RefluxStop, its implant-based treatment for acid reflux.
-
Lilly launches taRNA vaccine partnership
Pharma giant Eli Lilly has entered into a collaboration with the Boston‑based biotech company Amplitude Therapeutics to develop taRNA‑based vaccine candidates a...
-
Isotope deal boosts Uppsala radiotherapy company
Uppsala‑based Akiram Therapeutics has signed an agreement with Germany’s ITM for the supply of lutetium‑177 to support the continued development of the company’...
-
ZEISS CLINIC 360 receives FDA 510k clearance
The ZEISS CLINIC 360 all-in-one browser-based software solution aggregates clinical data at scale and powers advanced analytics for streamlined ophthalmic workf...
-
Melanoma data sends Moderna shares skyrocketing
A vaccine candidate from Moderna and Merck & Co almost halved the rate of skin cancer recurrence in a late-stage trial, the two companies report. The announceme...
-
Coloplast delays introduction of new incontinence system
Originally scheduled for release within the financial year ending in september this year, Coloplast now expects the FDA clearence of its Intibia system no earli...
-
“We develop vaccines no one else is developing”
Vaccines delivered via patches rather than injections. Future solutions could fundamentally reshape global health. Meet the man leading efforts to distribute va...
-
CEO change at Bico – ”The timing is right”
Bioconvergence company Bico Group is promoting its Chief Commercial Officer, Anders Fogelberg, to the CEO position, while current CEO and President Maria Forss ...
-
BioArctic steps into cancer research with new collaboration
BioArctic has entered a research collaboration with the Swedish‑Japanese company Mesenkia Therapeutics, marking the company’s first step into the oncology field.
-
New FDA setback for Xspray – stock plunges
The Swedish research company Xspray Pharma has received yet another negative decision from the U.S. Food and Drug Administration (FDA), linked to the company’s ...
-
Trump expected to pick Heidi Overton to lead the FDA
Donald Trump is expected to nominate Heidi Overton as the new commissioner of the US Food and Drug Administration (FDA), according to several international media outlets.
-
LEO Pharma acquires dermatology drug for 435 million USD
LEO Pharma strengthens its dermatology portfolio by acquiring the late-stage drug candidate dersimelagon.
-
Pila Pharma cleared to begin obesity trial
Swedish–Danish Pila Pharma has received approval from the European Medicines Agency (EMA) to begin a clinical trial of the company’s drug candidate for obesity.
-
Life sciences fuel Greater Copenhagen's economic growth
The expansion of the life sciences sector on the Danish side of the Øresund is a key reason why the Danish-Swedish Greater Copenhagen region has emerged as one ...
-
Sanofi cuts 229 jobs following $9.1bn acquisition
A new round of job cuts is hitting the US biotech hub of Massachusetts. Sanofi is cutting 229 positions and closing former Blueprint offices, while Merck KGaA i...
-
Evaxion drops solid tumour vaccine to advance new glioblastoma program
Danish biotech company Evaxion is discontinuing a vaccine candidate for solid tumors and redirecting resources to a program specifically aimed at brain cancer.
-
CAR‑T developer Elicera appoints new CEO
Swedish CAR‑T developer Elicera has appointed Johan Liwing as its new CEO, succeeding Jamal El‑Mosleh, who is stepping down.
-
Potions, Placebos and Perilous Practices – Macabre Mistakes in the History of Medicine
Tobacco for cancer, heroin for coughs, mercury for teething babies. Humanity’s path towards today’s evidence‑based medicine has been lined with strange misjudge...
-
OCTONIQ, Ett smart, modulärt CIP-system.
OCTONIQ, ett modulärt CIP-system från AxFlow Systems som effektivt rengör din anläggning med hög precision. Systemet minskar förbrukningen av både vatten, energ...
-
“Ozempic babies” – myth or reality?
Have weight-loss drugs such as Ozempic led to a rise in unplanned pregnancies? Life Science Sweden takes a closer look.
BREAKING